Analysis of the action of euxanthone, a plant-derived compound that stimulates neurite outgrowth

We have investigated the neurite growth-stimulating properties of euxanthone, a xanthone derivative isolated from the Chinese medicinal plant Polygala caudata. Euxanthone was shown to exert a marked stimulatory action on neurite outgrowth from chick embryo dorsal root ganglia explanted in collagen gels, in the absence of added neurotrophins. It was also shown to promote cell survival in explanted chick embryo ganglia, and to stimulate neurite outgrowth from isolated adult rat primary sensory neurons in vitro. The further finding that euxanthone stimulates neurite outgrowth from explants of chick embryo retina and ventral spinal cord suggests an action on signaling pathways downstream of neuronal receptors for specific neurotrophic factors. Consistent with this, euxanthone did not promote neurite outgrowth from non-transfected PC12 cells, or from PC12 cells transfected with TrkB or TrkC, under conditions in which these cells extended neurites in response to, respectively, the neurotrophins nerve growth factor, brain-derived neurotrophic factor and neurotrophin 3. Western blot analysis of euxanthone-stimulated dorsal root ganglion explants showed that expression of phospho-mitogen-activated protein (MAP) kinase was up-regulated after 1 h of euxanthone-treatment. Inhibition of the MAP kinase pathway using PD98059, a specific inhibitor of MAP kinase kinase, blocked all euxanthone-stimulated neurite outgrowth. However, analysis of phospho-Akt expression indicated that the phosphatidylinositol-3 kinase-Akt pathway, another major signaling pathway engaged by neurotrophins, is not significantly activated by euxanthone. These results suggest that euxanthone promotes neurite outgrowth by selectively activating the MAP kinase pathway.     

Harvey Cushing's Early Operative Treatment of Skull Base Fractures

Objectives To review Dr. Harvey Cushing''s early surgical cases at the Johns Hopkins Hospital, revealing details of his operative approaches to fractures of the skull base. Design Following institutional review board approval and through the courtesy of the Alan Mason Chesney Archives, we reviewed the Johns Hopkins Hospital surgical files. Setting The Johns Hopkins Hospital, 1896 to 1912. Participants A total of 24 patients underwent operative treatment for suspected fractures of the skull base. Main Outcome Measures The main outcome measure was operative approach, postoperative mortality, and condition recorded at the time of discharge. Results Overall, 23 patients underwent operative treatment for suspected skull base fractures. The mechanisms of injury were known for 22 patients and included work-related injuries (41%), falls (23%), vehicle injuries (32%), and other trauma (5%). One patient had no mechanism of injury specified in the file. The outcome at the time of discharge from the hospital was “well” or “improved” in 12 patients (52%). The remaining 11 patients died during their admission. Conclusions Although Cushing''s experience with selected skull base pathology has been previously reported, the breadth of his contributions to operative approaches to the skull base has been neglected.     

Enhanced electrochemical response of a modified glassy carbon electrode by poly(2-vinlypyridine-b-methyl methacrylate) conjugated gold nanoparticles for detection of nicotine

Poly(2-vinylpyridine-b-methylmethacrylate) coated gold nanoparticles [P(2VP-MMA)-AuNPs] were prepared and characterized by UV-Vis, FTIR, AFM, and zetasizer analysis. Investigation of the potential of the synthesized poly(2-vinylpyridine-b-methylmethacrylate) coated gold nanoparticles [P(2VP-MMA)-AuNPs] for detection of nicotine is the main focus of the current study. P(2VP-MMA)-AuNPs were coated on a glassy carbon electrode (GCE) for electrochemical detection of nicotine by cyclic voltammetry. The effect of molar mass of individual P2VP blocks and total molar mass of the block copolymer is evaluated in the context of an enhanced electrochemical response of the modified GCE for its sensing ability of nicotine in both aqueous and organic media. The electrochemical detection of nicotine is significantly enhanced by modification of the GCE with P(2VP-MMA)-AuNPs.

Poly(2-vinylpyridine-b-methylmethacrylate) coated gold nanoparticles [P(2VP-MMA)-AuNPs] are employed for enhancement of electrochemical response of glassy carbon electrode for nicotine.     

Survival of patients receiving fibrinolytic therapy for acute ST-segment elevation myocardial infarction in a developing country – patient characteristics and predictors of mortality

There is paucity of outcomes data on patients receiving fibrinolytic therapy (FT) for acute ST-elevation myocardial infarction (STEMI) in Indo-Asians. We conducted this study to determine survival as well as correlates of mortality in this population. Hospital charts of 230 patients receiving FT for acute STEMI between January 2002 and December 2004 were reviewed. Primary outcome variable was total mortality. Cox proportional hazards regression models were constructed. At a median follow-up of 717 days, 13.5% died, majority (23) during the in-hospital period. Multivariate predictors of mortality included (adjusted hazards ratio [HR], 95% confidence interval [CI]) age (HR 1.06, 95% CI 1.01–1.13), ejection fraction (HR 0.93, 95% CI 0.89–0.97), admission white cell count (HR 1.02, 95% CI 1.01–1.04) and change in ST-segment elevation (HR 0.96, 95% CI 0.92–0.99). We conclude that patients receiving FT for acute STEMI in Pakistan are a relatively high-risk group with a 10% in-hospital mortality and high frequency of recurrent events. Comparison data with primary angioplasty as an alternative strategy are needed.     

Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment

The Asian Pacific Association for the Study of the Liver (APASL) Working Party on Portal Hypertension has developed consensus guidelines on the disease profile, diagnosis, and management of noncirrhotic portal fibrosis and idiopathic portal hypertension. The consensus statements, prepared and deliberated at length by the experts in this field, were presented at the annual meeting of the APASL at Kyoto in March 2007. This article includes the statements approved by the APASL along with brief backgrounds of various aspects of the disease.